NEW YORK (GenomeWeb News) – Osmetech today said that Thermo Fisher Scientific division Fisher HealthCare will distribute its eSensor XT-8 instrument platform and molecular diagnostic tests and consumables in the US.
The distribution agreement has a term of five years. Financial and other details were not disclosed.
"As we roll out our esensor XT-8 platform, Fisher Healthcare's considerable sales and marketing strength and established relationship with key customer accounts will play an important role in accelerating our market penetration," Osmetech CEO James White said in a statement.
Last July, Osmetech received US Food and Drug Administration 510(k) clearance for the eSensor platform and for its warfarin sensitivity test.